Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Alnylam Pharmaceuticals Inc Market Cap
The Alnylam Pharmaceuticals Inc (ALNY) share price is expected to increase by 8.06% over the next year. This is based on calculating the average 12-month share price estimate provided by 18 stock analysts who have covered ALNY. Price targets range from $160.5 at the low end to $400 at the high end. The current analyst consensus for ALNY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 18 Wall Street analysts have assigned ALNY 13 buy ratings, 4 hold ratings, and 1 sell ratings. This means that analysts expect Alnylam Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ALNY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ALNY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Luca Issi RBC Capital | Outperform | $300 | Reiterates | Sep 19, 2024 |
| Olivia Brayer Cantor Fitzgerald | Neutral | $220 | Reiterates | Sep 9, 2024 |
| Tazeen Ahmad B of A Securities | Buy | $307 | Maintains | Sep 4, 2024 |
| Luca Issi RBC Capital | Outperform | $300 | Reiterates | Sep 4, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $400 | Reiterates | Aug 30, 2024 |
| Jessica Fye JP Morgan | Neutral | $280 | Maintains | Aug 26, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $400 | Reiterates | Aug 20, 2024 |
| Salveen Richter Goldman Sachs | Buy | $370 | Upgrade | Aug 16, 2024 |
| Joseph Stringer Needham | Buy | $320 | Maintains | Aug 2, 2024 |
| David Lebovitz Citigroup | Buy | $342 | Maintains | Aug 2, 2024 |
| Salveen Richter Goldman Sachs | Neutral | $198 | Maintains | Aug 2, 2024 |
| Tiago Fauth Wells Fargo | Equal-Weight | $233 | Maintains | Aug 2, 2024 |
| Luca Issi RBC Capital | Outperform | $300 | Maintains | Aug 2, 2024 |
| Whitney Ijem Canaccord Genuity | Buy | $366 | Maintains | Aug 2, 2024 |
| Gena Wang Barclays | Overweight | $295 | Maintains | Aug 2, 2024 |
| Gary Nachman Raymond James | Outperform | $275 | Maintains | Aug 2, 2024 |
| Olivia Brayer Cantor Fitzgerald | Neutral | $220 | Maintains | Jul 22, 2024 |
| Michael Ulz Morgan Stanley | Equal-Weight | $255 | Maintains | Jul 12, 2024 |
| Whitney Ijem Canaccord Genuity | Buy | $357 | Maintains | Jul 8, 2024 |
| Jessica Fye JP Morgan | Neutral | $248 | Maintains | Jul 3, 2024 |
When did it IPO
2004
Staff Count
2,100
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Market Cap
$34.40B
In 2023, ALNY generated $1.83B in revenue, which was a increase of 76.23% from the previous year. This can be seen as a signal that ALNY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 01 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have shown performance metrics against their sector for the current year.
Why It Matters - Performance comparisons highlight how ALNY and CORT are faring relative to their sector, indicating market trends, investor sentiment, and potential investment opportunities.
Wed, 02 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Alnylam's revenues are increasing due to strong sales of Amvuttra and Givlaari, with positive progress in collaboration deals with RHHBY, NVS, and REGN.
Why It Matters - Strong sales of Amvuttra and Givlaari enhance Alnylam's revenue, while successful collaborations with major firms indicate growth potential and market confidence.
Sun, 29 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Alnylam Pharmaceuticals presented new data from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy at the HFSA Annual Scientific Meeting 2024.
Why It Matters - Alnylam Pharmaceuticals' new data on vutrisiran may enhance its market position in treating ATTR-CM, potentially impacting stock performance and investor sentiment toward the company.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Alnylam Pharmaceuticals will host a TTR Investor Day webcast on October 9, 2024, at 8:30 am ET. A replay will be available on their website within 48 hours post-event.
Why It Matters - Alnylam Pharmaceuticals' TTR Investor Day could reveal strategic insights and updates that may impact stock performance, attracting investor interest and influencing market sentiment.
Thu, 12 Sep 2024
Sentiment - POSITIVE
Source - MarketBeat
Summary - Alnylam Pharmaceuticals (NASDAQ: ALNY) stock has gained 100% over the past two years, driven by rising expectations for a market-disrupting heart treatment.
Why It Matters - Alnylam's 100% stock gain signals strong market confidence in its innovative heart treatment, potentially positioning it for significant future growth and increased investor returns.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - WSJ
Summary - Obscure diseases may present significant opportunities for drug companies, potentially leading to lucrative market prospects in niche therapeutic areas.
Why It Matters - Obscure diseases can lead to significant market potential for drug companies, potentially driving revenue growth and investment returns as they cater to unmet medical needs.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
